Summarized by Masters of Longevity from FDA - Press Releases.
Rare disease drug development receives a roadmap-style policy discussion promising a holistic, fit-for-purpose regulatory approach; ideal for stakeholders tracking regulatory strategy change.
Key Takeaways
- The FDA is initiating a program to redesign drug and biologic development pathways specifically for rare diseases.
- The initiative aims to create a holistic, fit-for-purpose regulatory framework tailored to the unique challenges of rare disease trials.
- The framework will support more flexible approaches to evidence generation and decision-making for rare disease therapies.
